Quest Diagnostics Reports Strong Q2 2026 Performance with Revenue Growth and Strategic Collaborations
Quest Diagnostics reported strong second-quarter performance in 2026, driven by over 10% organic revenue growth across physician, hospital, and consumer channels. The company attributed this to strategic collaborations such as those with Corewell Health and Fresenius Medical Care, which contributed nearly 9% of total volume through the Co-Lab partnership model. Revenue per requisition increased by 2.9%, excluding business mix impacts, due to more tests per order and a shift toward high-value diagnostics in areas like brain health, cardiometabolic conditions, and oncology. Management noted margin pressures from wage increases and Project Nova investments but highlighted productivity gains through automation and AI. Quest raised its full-year 2026 guidance for both revenue and EPS due to strong first-half performance. The company expects operating margin expansion despite headwinds like higher fuel costs and concentrated spending in the second half of the year.
Tickers: $DGX
Topics: earnings operational performance revenue growth strategic partnerships